Update on Anti-obesity Medications

被引:0
|
作者
Park, Kyung-Hee [1 ]
机构
[1] Hallym Univ, Coll Med, Sacred Heart Hosp, Dept Family Med, Chunchon, South Korea
来源
关键词
Obesity; Pharmacotherapy; Orlistat; Sibutramine;
D O I
10.5124/jkma.2005.48.9.896
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Obesity results from an imbalance between energy intake and energy expenditure. Drugs can shift this balance in a favorable way by reducing food intake, altering metabolism, and by increasing energy expenditure. All patients with obesity should make efforts to change their lifestyle behaviors to decrease energy intake and increase physical activity. Lifestyle modifications also should be a component of all other levels of therapy. Pharmacotherapy can be a useful adjunctive measure for well-selected patients. Anti-obesity pharmacological treatment is indicated when the patient's body mass index (BMI) is > 25 kg/m(2) or when the patient's BMI is > 23 kg/m(2) with co-morbidities such as diabetes, hypertension, hypercholesterolemia, and coronary artery disease. Obesity is a chronic disease that requires long-term therapy for successful long-term weight management. Often, the patients regain their lost weight after therapy is discontinued, so it should be stressed that obesity is not a curable disease, and thus the maintenance of the reduced weight is very important. Obese patients must be examined in detail regarding mood, obesity-related complications or conditions, current medications, eating habits, and history of drug side-effects. The physicians' choice for anti-obesity medications is based on both the patient's medical conditions and long-term safety and efficacy of anti-obesity drugs.
引用
收藏
页码:896 / 903
页数:8
相关论文
共 12 条
  • [1] Bupropion SR enhances weight loss: A 48-week double-blind, placebo-controlled trial
    Anderson, JW
    Greenway, FL
    Fujioka, K
    Gadde, KM
    McKenney, J
    O'Neil, PM
    [J]. OBESITY RESEARCH, 2002, 10 (07): : 633 - 641
  • [2] BRAY GA, 2004, HDB OBESITY CLIN APP, P201
  • [3] Zonisamide for weight loss in obese adults - A randomized controlled trial
    Gadde, KM
    Franciscy, DM
    Wagner, HR
    Krishnan, KRR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (14): : 1820 - 1825
  • [4] GOLDSTEIN DJ, 1994, INT J OBESITY, V18, P129
  • [5] Hansen DL, 2004, INT J OBESITY, V28, P378
  • [6] Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials
    Hutton, B
    Fergusson, D
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2004, 80 (06): : 1461 - 1468
  • [7] Effect of sibutramine on weight loss and blood pressure: A meta-analysis of controlled trials
    Kim, SH
    Lee, YM
    Jee, SH
    Nam, CM
    [J]. OBESITY RESEARCH, 2003, 11 (09): : 1116 - 1123
  • [8] Norris SL, 2005, COCHRANE DB SYST REV, V25
  • [9] One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes - A radomized trial
    Redmon, JB
    Raatz, SK
    Reck, KP
    Swanson, JE
    Kwong, CA
    Fan, Q
    Thomas, W
    Bantle, JP
    [J]. DIABETES CARE, 2003, 26 (09) : 2505 - 2511
  • [10] XENical in the prevention of diabetes in obese subjects (XENDOS) study
    Torgerson, JS
    Hauptman, J
    Boldrin, MN
    Sjöström, L
    [J]. DIABETES CARE, 2004, 27 (01) : 155 - 161